Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-deoxy-2,3-dehydro-N-acetylneuraminic acid** is a synthetic small molecule derivative of N-acetylneuraminic acid (sialic acid) in which the hydroxy group at C‑2 is removed and the molecule is reduced across the 2,3-bond. It acts as a potent inhibitor of neuraminidases (sialidases) from viral (including influenza), bacterial, and mammalian sources by binding to their catalytic site as a transition state analog. This compound has been widely used in biochemical research to study sialidase function and glycoprotein interactions. It also serves as a lead structure for drug design targeting neuraminidase activity and has been explored for potential use in vaccine development and diagnostics[1][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.